| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | estrogen | 한글 | 에스트로겐 |
|---|---|---|---|
| 설명 | 난소안에 있는 난포에서 분비되는 난포호르몬의 총칭. 여포호르몬, 발정 호르몬이라고도 한다. 에스트로겐이란 생물학적인 명칭이며 동물의 발정작용 외에 여러 가지 작용을 지닌 물질의 총칭이다. 사람에는 20종 이상의 에스트로겐의 종류가 있지만, 그중에서도 estrone, estradiol, estriol의 3가지가 가장 중요하다. 에스트로겐은 비임신시에는 여포호르몬의 조절에 의해서, 주로 난소에서 생성되며, 임신시에는 주로 태반에서 만들어지지만, estriol은 태아의 부신과 태반의 합동작용에 의해서 만든다. 사람에게 있어서 에스트로겐의 주된 작용은 다음과 같은 것이 있다. 1. 제 2차 성징의 발현. 2. 내성기, 질, 외성기의 발육촉진 3. 자궁내막 및 성기 상피의 증식 4. 배란기에 자궁의 입구인 목에 점액을 증량시켜 정자의 통과성을 좋게 한다. 5. 임신시에 성기와 유방 등에 임신성 변화를 일으킨다. 6. 성기의 근육을 증식시켜 운동성을 증가시킨다. 7. 단백질 지질, 무기질 등의 물질대사나 여러 가지 효소의 작용에 영향을 준다. 8. 배란과 생리 주기의 유지에 관여한다. |
||
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
|---|---|
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| ERP | early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr... |
| ER | 1) Emergency Room; 응급실 2) Estrogen Receptor |
| ER | Estrogen Receptor |
|---|---|
| ER-ICA | Estrogen receptor immunocytochemical assay |
| ER | Estrogen receptor alpha |
| ER alpha | Estrogen receptor alpha |
| ERbeta | Estrogen receptor alpha and beta |
| estrogen | <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones. In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo. Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders. (18 Nov 1997) |
|---|---|
| estrogen 2-hydroxylase | <enzyme> Same enzyme for hydroxylation in 2 or 4 position Registry number: EC 1.14.99.- Synonym: estrogen 4-hydroxylase, ethinylestradiol 2-hydroxylase (26 Jun 1999) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor kinase | <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor Registry number: EC 2.7.1.- Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2 (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| GABA receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
| gamma aminobutyric acid receptor | <physiology> Ligand gated chloride ion channel forming receptor opened by gamma aminobutyric acid. Two distinct types: A and B. A receptor: One of a family of neurotransmitter receptors with fast intrinsic ion channels that includes the glycine receptor and the nicotinic acetylcholine receptor. Distinct from another major receptor family, the muscarininc acetylcholine receptor and rhodopsin, with no intrinsic ion channel. The A receptor is specifically blocked by bicuculline. It consists of two pairs of protein chains forming an A2B2 complex, the A chains bind benzodiazepine and the B chains bind GABA. The 4 subunits are thought to form a tight group with the chloride channel in the middle. There is considerable similarity between the amino acid sequences of the receptor subunits and those of the nicotinic acetylcholine receptor suggesting that both receptors are derived from some evolutionary ancestor. See: amino acid receptor superfamily. B receptor: Brain receptor (80 kD) for the inhibitory neurotransmitter gamma amino butyric acid. Differs from the A receptor both in agonist specificity (baclofen is a specific agonist) and its effects on cells. It modulates intracellular calcium levels through a Go mediated effect on N type calcium channels and also lowers intracellular cAMP levels by an effect on adenylyl cyclase, thereby reducing the secretion of catecholamines. (05 Jan 1998) |
| GAP-1 receptor tyrosine kinase | <enzyme> Similar to rasGTPase-activating proteins; inhibits signaling activity of let-60; amino acid sequence given in first source Registry number: EC 2.7.1.- Synonym: gap-1 gene product, gap-1 protein (26 Jun 1999) |
Synonyms : ERalpha, Estradiol Receptor alpha, Estrogen Receptor 1, Estrogen Receptors alpha, Receptor alpha, Estrogen, Receptor alpha, Estradiol, alpha, Estradiol Receptor
Synonyms : ERbeta, ERbetacx, Estrogen Receptor 2, Estrogen Receptors beta, Receptor beta, Estrogen
Synonyms : Antiestrogen, Estrogen Receptor Modulator, Modulator, Estrogen Receptor, Modulators, Estrogen Receptor, Receptor Modulator, Estrogen, Receptor Modulators, Estrogen
| estrogen receptor |
Blood test used to detect tumor cells in patients with breast cancer
출처: www.umdnj.edu/hsweb/research_glossary/e.htm
|
|---|---|
| estrogen receptor |
ER. Protein found on some cancer cells to which estrogen will attach.
출처: www.spineuniverse.com/community/cancerdictionary.h...
|
| estrogen receptor |
Belonging to the class of nuclear receptors, estrogen receptors are ligand-activated nuclear proteins present in many breast cancer cells that are important in the progression of hormone-dependent cancers. After binding, the receptor-ligand complex activates gene transcription. There are two types of estrogen receptors (a and ?. ERa is one of the most important proteins controlling breast cancer function. ...
출처: www.jco.org/cgi/glossarylookup
|
| estrogen receptor |
a protein molecule dissolved in the aqueous nuclear medium that is coded for estrogen.
출처: www.cem.msu.edu/~cem181fp/schitzo/glossary.html
|
| estrogen receptor status |
The presence or absence of a receptor to the hormone estrogen on breast cancer cells. Tumors that possess receptors either to estrogen alone or to both estrogen and progesterone are more responsive to estrogen-blocking a
출처:
|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|